BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32561529)

  • 1. ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.
    Duncan RM; Reyes L; Moats K; Robinson RM; Murphy SA; Kaur B; Stessman HAF; Dolloff NG
    Cancer Res; 2020 Aug; 80(16):3279-3291. PubMed ID: 32561529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATF3 Repression of BCL-X
    Chüeh AC; Tse JWT; Dickinson M; Ioannidis P; Jenkins L; Togel L; Tan B; Luk I; Davalos-Salas M; Nightingale R; Thompson MR; Williams BRG; Lessene G; Lee EF; Fairlie WD; Dhillon AS; Mariadason JM
    Clin Cancer Res; 2017 Sep; 23(18):5573-5584. PubMed ID: 28611196
    [No Abstract]   [Full Text] [Related]  

  • 3. PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma.
    Robinson RM; Basar AP; Reyes L; Duncan RM; Li H; Dolloff NG
    Cancer Chemother Pharmacol; 2022 May; 89(5):643-653. PubMed ID: 35381875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.
    Fujisawa T; Joshi BH; Puri RK
    J Transl Med; 2011 Apr; 9():37. PubMed ID: 21477288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.
    Liu J; Edagawa M; Goshima H; Inoue M; Yagita H; Liu Z; Kitajima S
    Biochem Biophys Res Commun; 2014 Mar; 445(2):320-6. PubMed ID: 24530917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.
    Sooraj D; Xu D; Cain JE; Gold DP; Williams BR
    Mol Cancer Ther; 2016 Jul; 15(7):1726-39. PubMed ID: 27196751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
    Hao ZF; Su YM; Wang CM; Yang RY
    Tumour Biol; 2015 Mar; 36(3):1471-6. PubMed ID: 25371069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bZIP repressor proteins, c-Jun dimerization protein 2 and activating transcription factor 3, recruit multiple HDAC members to the ATF3 promoter.
    Darlyuk-Saadon I; Weidenfeld-Baranboim K; Yokoyama KK; Hai T; Aronheim A
    Biochim Biophys Acta; 2012; 1819(11-12):1142-53. PubMed ID: 22989952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes.
    Xu S; Liu Y; Yang K; Wang H; Shergalis A; Kyani A; Bankhead A; Tamura S; Yang S; Wang X; Wang CC; Rehemtulla A; Ljungman M; Neamati N
    Theranostics; 2019; 9(8):2282-2298. PubMed ID: 31149044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Mechanistic Elucidation of a Class of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma.
    Kyani A; Tamura S; Yang S; Shergalis A; Samanta S; Kuang Y; Ljungman M; Neamati N
    ChemMedChem; 2018 Jan; 13(2):164-177. PubMed ID: 29235250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
    Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
    Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling.
    Li Y; Li Z; Zhang C; Li P; Wu Y; Wang C; Bond Lau W; Ma XL; Du J
    Circulation; 2017 May; 135(21):2041-2057. PubMed ID: 28249877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the ATF3 gene through a co-ordinated amino acid-sensing response programme that controls transcriptional regulation of responsive genes following amino acid limitation.
    Pan YX; Chen H; Thiaville MM; Kilberg MS
    Biochem J; 2007 Jan; 401(1):299-307. PubMed ID: 16989641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
    Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
    Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
    Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
    J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni.
    Anderson L; Gomes MR; daSilva LF; Pereira ADSA; Mourão MM; Romier C; Pierce R; Verjovski-Almeida S
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005539. PubMed ID: 28406899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.
    Kang SH; Seok YM; Song MJ; Lee HA; Kurz T; Kim I
    Mol Pharmacol; 2015 May; 87(5):782-91. PubMed ID: 25667225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.
    To KK; Polgar O; Huff LM; Morisaki K; Bates SE
    Mol Cancer Res; 2008 Jan; 6(1):151-64. PubMed ID: 18234970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.